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Edited by Beat ImhofAbstract To identify the elements of two chemokines [mono-
cyte chemoattractant protein-1 (MCP-1) and eotaxin] that
control their diﬀerential recognition by their respective receptors
(CCR2 and CCR3), we have studied the receptor interactions of
MCP-1-eotaxin chimeras. Each receptor was found to exhibit a
distinct binding preference for proteins containing the amino-
terminal region of the cognate chemokine for that receptor.
However, other elements dictating chemokine preference were
diﬀerent for the two receptors. In some cases, the inﬂuence of
replacing a particular region was dependent on the identities of
neighboring regions, indicating a complex network of coopera-
tive and/or compensating interactions.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Chemokines are small proteins that activate G-protein-
coupled receptors to trigger the migration and accumulation of
leukocytes, a central component of both normal and patho-
logical inﬂammatory conditions [1–4]. In addition, activation
of chemokine receptors located on tumor cells can control the
tissue destinations of metastatic cancer cells [5,6] and certain
chemokine receptors can act as co-receptors for infection of
leukocytes by HIV [7–9]. There are 45 known human chemo-
kines, classiﬁed into two major families (‘CC’ and ‘CXC’) and
19 known human chemokine receptors [10,11]. Most chemo-
kines can bind and/or activate several, but not all, receptors
and most receptors can bind and/or be activated by several,
but not all, chemokines within one family.
In an eﬀort to decipher the complicated chemokine-receptor
recognition code, there have been numerous studies of the
structures and structure-activity relationships of chemokines
[12–14]. These studies have identiﬁed the roles of certain amino
acid residues in mediating the interactions of speciﬁc chemo-
kines with their receptors. However, they have provided lim-
ited information regarding the elements that allow a particular
receptor to distinguish between diﬀerent chemokines. In this* Corresponding author. Fax: +1-812-855-8300.
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doi:10.1016/j.febslet.2004.06.079letter, we describe an initial exploration of the features dic-
tating chemokine-speciﬁcity using a series of chimeric chemo-
kines containing elements from each of two natural CC
chemokines, eotaxin and monocyte chemoattractant protein-1
(MCP-1). These chemokines share 65% sequence identity.
However, the receptor CCR2 binds 130-fold more tightly to
MCP-1 than to eotaxin, whereas the receptor CCR3 binds
60-fold more tightly to eotaxin than to MCP-1 [15]; the
chemokine concentrations required for half-maximal receptor
activation roughly parallel the binding aﬃnities. Thus, these
structurally similar but functionally distinct proteins provide
an excellent opportunity to explore speciﬁcity determinants of
chemokines.2. Materials and methods
2.1. Chemokine expression and puriﬁcation
Genes encoding the six chimeric chemokines were made from syn-
thetic oligonucleotides using recursive PCR [16], then subcloned into a
pET expression vector (Novagen, Madison, WI): pET-11a (for EE-
MMM and EMMMM) or pET-30a (for other constructs). Each con-
struct encodes a fusion protein consisting of an N-terminal (His)6-tag,
a protease cleavage site, and the desired protein sequence. The protease
cleavage site [Factor Xa site (IEGR) for MEEMM, in which the N-
terminus is that of MCP-1; modiﬁed thrombin site (LVPRGP) [17] for
all other constructs] was chosen to allow proteolytic release of the
correct protein sequence without any N-terminal extension.
Wild type MCP-1 was purchased from R&D Systems (Minneapolis,
MN). Wild type eotaxin and chimeric chemokines were expressed and
puriﬁed using the protocol previously described for wild type eotaxin
[17], with the following modiﬁcations: (1) vectors derived from pET-
11a were transformed into Origami E. coli cells (Novagen, Madison,
WI) instead of BL21(DE3) cells; (2) for expression of EEMEM and
MEEMM, the growth temperature was reduced to 25 C after in-
duction; and (3) for MEEMM, the (His)6-tag was removed by treat-
ment with Factor Xa (0.05 mg/mL Factor Xa in 50 mM Tris, 100 mM
NaCl, and 2 mM CaCl2, pH 8.0, room temperature, 5 days). The
molecular weights of all proteins were veriﬁed by MALDI-TOF mass
spectrometry. Protein concentrations were determined using the ex-
tinction coeﬃcients at 280 nm calculated from the protein sequences:
EEMMM and EEMEM¼ 7210 M1 cm1, all others¼ 8490
M1 cm1 [18].
2.2. Receptor binding and activation assays
Cell-based assays were performed using CHO cells stably trans-
formed to express CCR2 or versions of CCR3 bearing N-terminal
FLAG (MDYKDDDD) or His6 (MHHHHHH) epitope-tags (Flag-
CCR3 and His6-CCR3, respectively) [15]. CHO-CCR2 and CHO-His6-
CCR3 cell lines were used to perform calcium mobilization assays,
whereas competitive ligand binding data were gathered using the
CHO-CCR2 and CHO-FLAG-CCR3 cell lines. Detailed procedures
for cell-based assays are presented elsewhere [15]. Brieﬂy, CCR2 and
CCR3 binding assays were performed in duplicate using 125I-labeledation of European Biochemical Societies.
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tions of cold competitor chemokines. Binding data were ﬁt to the
equation: fraction bound¼ 1) 1/(1+(IC50/[chemokine])slope). Calcium
mobilization assays were performed in duplicate by monitoring in-
creases in the ratio of ﬂuorescence excitation at 340 and 380 nm
(kem ¼ 510 nm) after challenging Fura-2-loaded cells with varying
concentrations of chemokines. Dose–response data were ﬁt to the
equation: observed signal¼maximum signal/(1+([chemokine]/
EC50)
slope).3. Results
3.1. Design of chimeras
There are 26 amino acid positions that diﬀer between eo-
taxin and MCP-1. Based upon an analysis of the distances
between these non-conserved residues in eotaxin (Ca atoms for
Gly; Cb atoms for all other residues) [19], we deﬁned ﬁve re-
gions (labeled I–V), each representing a cluster of 4–6 spatially
proximal residues, as indicated in Fig. 1. Within the same
cluster, the average (S.D.) of inter-residue distances is
9.0 3.2 A, whereas the corresponding value for residues in
diﬀerent clusters is 22.5 7.1 A. For example, residue Leu-45
(region III) is 5.6–9.9 A from each other residue in region III,
but 11.6–30.1 A from each residue in other regions. One resi-
due, Gly-32, did not naturally fall into any of the initial ﬁve
regions based upon the distance analysis, but was subsequently
added to region V because it is located on the same face of the
chemokines as other region V residues.
There are thirty two (25) possible combinations of the ﬁve
regions deﬁned in Fig. 1. In this initial study, we have exam-
ined a subset (eight) of these proteins, six chimeras and the two
wild type chemokines; these are represented schematically in
Fig. 1C. Chimeras EEEEM, EEEMM, EEMMM, and EM-
MMM involve successive replacement of regions V, IV, III,
and II from eotaxin with the corresponding regions from
MCP-1; subsequent replacement of region I gives wild type
MCP-1. This set of six proteins was selected to provide ﬁve
pairwise comparisons in which individual chemokines diﬀer inFig. 1. (A) 3D ribbon structural model of eotaxin (PDB code 1EOT; [23])
cylinders. Color coding indicates the composition of the ﬁve spatially deﬁne
Amino acid sequence alignment of eotaxin and MCP-1, with numbering corr
(A). (C) Composition of the two wild type and six chimeric chemokines, ind
each protein.a single region. The remaining two chimeras (EEMEM and
MEEMM) allow three additional pairwise comparisons and
therefore some insights into the context-dependence of binding
eﬀects (vide infra).
3.2. Receptor binding by chimeras
We have previously developed stable cell lines that express
CCR2 and epitope-tagged versions of CCR3 (FLAG-CCR3
and His6-CCR3) at very high levels [15]. The receptors in these
cell lines are competent for high aﬃnity chemokine-binding
and/or for activation by chemokines. In the present study, the
apparent aﬃnities of the wild type and chimeric chemokines
for CCR2 and FLAG-CCR3 were determined by competitive
radioligand binding assays, using these CHO cell lines. Data
for binding of wild type chemokines and representative chi-
meras to each receptor are presented in Fig. 2 and apparent
binding aﬃnities (IC50 values) for each ligand-receptor com-
bination are listed in Table 1. The two receptors have opposite
speciﬁcities for the wild type chemokines. For each receptor,
most chimeras display IC50 values intermediate between those
of the two natural chemokines.
3.3. Receptor activation by chimeras
The ability of each wild type chemokine and chimeric vari-
ant to activate CCR2 and CCR3 was evaluated by calcium
mobilization assays using the CHO cell lines expressing CCR2
and His6-CCR3. Dose–response curves for the wild type che-
mokines and representative chimeras are shown in Fig. 3.
Table 1 lists the ligand concentrations required for half max-
imal activation (EC50 values) and the maximum levels of wild
type activity observed (relative to those for the relevant wild
type chemokine). In most cases, the variations in EC50 values
follow similar trends to those observed for IC50 values; two
exceptions are discussed below. Finally, there was some vari-
ation in the peak levels of activation observed for diﬀerent
chemokine constructs on the same receptor. These could po-
tentially reﬂect diﬀerences in the kinetics of receptor activation
[20]. Alternatively, they could arise from diﬀerences in the ﬁnalwith the non-conserved residues (with respect to MCP-1) shown as
d regions (I, red; II, orange; III, yellow; IV, green; and V, cyan). (B)
esponding to that of eotaxin. Non-conserved residues are colored as in
icating which regions are derived from eotaxin (E) and MCP-1 (M) in
Fig. 3. Receptor activation by chemokines. Shown are dose–response
curves for calcium mobilization in (A) CHO-CCR2 cells and (B) CHO-
His6-CCR3 cells treated with increasing concentrations of wild type
chemokines [MCP-1 ðdÞ and eotaxin ðsÞ] and selected chimeras
[EEMMM ðÞ, EEEMM ðrÞ, EEEEM ðÞ, and EMMMM ðjÞ].
Data and error bars are averages and standard errors from duplicate
independent data sets. Solid lines are ﬁts to the equation given in
Section 2.
Fig. 2. Competitive radioligand-binding assays. Shown are competi-
tion data for displacement of (A) 125I-MCP-1 from CHO-CCR2 cells
and (B) 125I-eotaxin from CHO-FLAG-CCR3 cells using increasing
concentrations of wild type chemokines [MCP-1 ðdÞ and eotaxin ðsÞ]
and selected chimeras [EEMMM ðÞ, MEEMM ðnÞ, and EMMMM
ðjÞ]. Data and error bars are averages and standard errors from du-
plicate independent data sets. The solid lines are ﬁts to the equation
given in Section 2.
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diﬀerent chemokines [21].4. Discussion
4.1. Speciﬁcity of chemokine binding by receptors
Fig. 4 displays the changes in receptor binding aﬃnities
(IC50 ratios) observed for each of the eight pairs of chemokines
that diﬀer only in a single region; for regions I, III, and IV, two
independent pairwise comparisons can be made, labeled ‘a’Table 1
Receptor binding and activation data for wild type chemokines and chimera
Receptor CCR2
Chemokine IC50 (nM) EC50 (nM) % Wild type activity
Eotaxin 20.2 1.5 100–400 73
EEEEM 4 1 28 2 73
EEEMM 1.7 0.7 9.1 0.1 57
EEMMM 2.9 0.5 8.9 0.9 73
EMMMM 0.6 0.1 11.7 0.7 97
EEMEM 3.1 0.7 22 5 55
MEEMM 1.1 0.4 50 10 88
MCP-1 0.15 0.03 0.7 0.2 100
a ‘‘% Wild type activity’’ is the magnitude of the calcium ﬂux signal observed w
same receptor (MCP-1 on CCR2 or eotaxin on CCR3).
bNo ﬂux detected at 200 nM.and ‘b’. IC50 ratios signiﬁcantly greater than one indicate that
the relevant receptor interacts more favorably with the swap-
ped region of the cognate chemokine than the corresponding
region of the non-cognate chemokine.
The data for binding to CCR2 (Fig. 4, solid bars) show that
replacement of region III or IV of MCP-1 by the corre-
sponding region of eotaxin has little eﬀect on CCR2-aﬃnity,
whereas replacement of region II or V reduces CCR2 aﬃnity
about 5-fold. The role of region I is less obvious. Comparisons
CCR3
a IC50 (nM) EC50 (nM) % Wild type activity
a
2.1 0.1 10 2 100
1.8 0.7 11 3 133
0.7 0.1 4.8 0.6 100
26 3 40 20 95
41 4 >150 113
2 1 16 5 117
18 3 b 0
130 20 b 0
ith the chemokine relative to that with the wild type chemokine on the
Fig. 5. Bar graph showing the ratios of EC50 values to IC50 values for
each wild type chemokine and chimera, assayed against CCR2 (solid
bars) and CCR3 (open bars). The composition of each chemokine is
shown schematically at the left, following the convention of Fig. 1C.
Arrows indicate cases in which EC50 values could not be determined
(see Table 1).
Fig. 4. Bar graph showing the ratios of IC50 values for pairwise
combinations of chemokines and chimeras. Solid and open bars
represent ratios of IC50 values for CCR2 and CCR3, respectively.
Each pair of bars is labeled (Roman numerals) according to the re-
gion that diﬀers between the two chemokines; for regions I, III, and
IV, the two independent pairwise comparisons are labeled ‘a’ and ‘b’.
For each pairwise comparison, the compositions of the two chemo-
kines/chimeras are represented schematically on the left following the
convention of Fig. 1C, with boxed letters indicating the regions that
diﬀer between each pair. Ratios of IC50 values were calculated for
CCR2 by dividing the IC50 for the bottom protein of each pair by the
IC50 for the top protein of the pair, while those for CCR3 were
calculated by dividing the IC50 for the top protein by the IC50 of the
bottom protein.
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of region I causes a 4-fold reduction in aﬃnity. However,
comparison Ib (between EEEMM and MEEMM) suggests
that region I plays a very minor role. Thus, the contribution
of region I is dependent on the identity of other structural
elements.
The data for binding to CCR3 (Fig. 4, open bars) also in-
dicate that replacement of region I can cause a substantial
reduction in receptor aﬃnity, although again the magnitude of
this eﬀect (3-fold for comparison Ia and 26-fold for com-
parison Ib) depends on the identity of other regions. However,
replacement of region II or V of eotaxin by the corresponding
region of MCP-1 has little or no eﬀect on CCR3 aﬃnity. On
the other hand, replacement of region III or IV can have a
substantial eﬀect on receptor aﬃnity, although, once again, the
eﬀects are dependent on the identity of neighboring regions. In
summary, CCR2 appears to utilize interactions with regions I,
II, and V, whereas CCR3 appears to utilize interactions with
regions I, III, and IV in order to distinguish between the two
chemokines.
The current data do not indicate precisely which amino acid
residues within each region are responsible for the observed
binding preferences. However, previous mutational studies
have provided evidence for the importance of some of the
swapped residues (Y13 of MCP-1 [22,23]; S4, V5, and F11 of
eotaxin [14]) in binding to CCR2 and CCR3. It seems likely
that some of these residues, in addition to providing aﬃnity for
the cognate receptor, also contribute to the chemokine-speci-
ﬁcity of the receptors. On the other hand, there are also several
residues that are identical in both MCP-1 and eotaxin yet
whose mutation decreases aﬃnity for the cognate receptors;
these include R24, K35, and K49 of MCP-1 [22,23] and R16
and I18 of eotaxin [14]. These residues are less likely to con-
tribute to the binding speciﬁcity of the receptors, except in
cases where their interactions are dependent on those of
neighboring non-conserved amino acids.4.2. Context-dependent eﬀects on binding
Substitution of region I causes a 4-fold reduction in CCR2
binding aﬃnity for comparison Ia (MCP-1 versus EM-
MMM), in which all other regions correspond to those of
MCP-1, but only a 1.5-fold reduction in comparison Ib
(MEEMM versus EEEMM), in which regions II and III both
correspond to those of eotaxin. In contrast, substitutions Ia
and Ib cause 3.3-fold and 26-fold reductions in CCR3
binding aﬃnity, respectively. Thus, the eﬀect on CCR3-
binding is much greater when regions II and III correspond to
those of eotaxin, whereas the eﬀect on CCR2-binding is
somewhat higher when regions II and III correspond to those
of MCP-1. This pattern is indicative of positive cooperativity
for the interactions of region I and region(s) II and/or III of a
particular chemokine with the cognate receptor for that
chemokine. Considering that region I is closer to region II
than to region III (minimum Cb–Cb distances of 11.3 and 22.8
A, respectively; Fig. 1A), we propose that the cooperativity is
between regions I and II. Notably, previous mutational data
indicate that residues in region II of both chemokines and
residues in region I of eotaxin contribute to receptor binding
aﬃnity [14,22–24].
The eﬀects of substituting regions III and IV on binding to
CCR3 are also dependent on the context of the substitutions.
The four chimeras EEMMM, EEEMM, EEMEM, and
EEEEM all contain regions I and II of eotaxin and region V of
MCP-1, but they diﬀer in regions III and IV (underlined),
covering all four possible substitution patterns in these regions.
For EEEMM, EEMEM, and EEEEM, in which region III
and/or region IV correspond(s) to that/those of eotaxin, the
apparent aﬃnity for CCR3 is in the range 0.7–1.8 nM, whereas
for EEMMM, in which both regions correspond to those of
MCP-1, the IC50 increases dramatically to 26 nM. This indi-
cates that optimal binding to CCR3 requires some element of
eotaxin region III or some element of eotaxin region IV, but
does not require both.
4.3. Receptor activation
Induction of transmembrane signals by chemokine receptors
is proposed to proceed via a two-step mechanism, involving
ﬁrst binding to the cognate chemokine, then a conformational
170 M.R. Mayer et al. / FEBS Letters 571 (2004) 166–170rearrangement coupled to G-protein activation [13,23]. Con-
sistent with the model that binding precedes, but is not suﬃ-
cient for, receptor activation, EC50 values are typically
somewhat higher than IC50 values. For MCP-1, eotaxin, and
most of the chimeras studied herein, the EC50/IC50 ratios are in
the range 2–10 (Table 1 and Fig. 5). Thus, reductions in the
ability to activate the receptors are generally correlated with
decreased binding aﬃnity. However, for MEEMM and EM-
MMM, concentrations 44-fold and 20-fold higher than the
IC50 values are required for half-maximal activation of CCR2,
suggesting that these chimeras can bind avidly to the inactive
state of the receptor but are deﬁcient in inducing the confor-
mational change to the activated state. Among all the che-
mokines studied herein,MEEMM and EMMMM are the only
two in which regions I and II are from diﬀerent chemokines.
Thus, we speculate that the ability to induce CCR2 activation
may depend upon cooperative interactions of these two regions
with the receptor.
4.4. Concluding remarks
The studies of chimeric chemokines described herein have
begun to reveal some of the elements of MCP-1 and eotaxin
that control diﬀerential chemokine recognition by their re-
spective receptors. The main conclusions are as follows. (1)
Each receptor has a distinct preference to interact with region I
(the N-terminus) of its cognate ligand over region I of the
other chemokine; this preference is most pronounced when
region II is also from the cognate chemokine. (2) CCR2 utilizes
interactions with regions II and V to enhance speciﬁcity for
MCP-1, whereas CCR3 uses mutually compensating interac-
tions with regions III and/or IV to increase speciﬁcity for eo-
taxin. (3) The contributions of each region to speciﬁcity are
sensitively dependent on the identities of nearby regions. Thus,
a thorough model to account for the observed recognition will
require, at a minimum, a consideration of the intrinsic con-
tributions of each region as well as the cooperativity between
each pair of regions. Finally, the data suggest that coopera-
tivity between regions may also be important in controlling
receptor activation following an initial binding event.
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